Business Segment Injectables Aspen’s injectable products are primarily administered in hospitals and also prescribed and administered by either physicians or in a retail pharmacy environment. These products focus on key therapeutic areas, including anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement therapies. Overview Key Brands Revenue Performance Arixtra Diprivan Fraxiparine Sustanon Ultiva Xylocaine Anticoagulant Generalanaesthetic Low molecularweight heparin Testosteronereplacementtherapy Opioid analgesicfor anaesthesia Regionalanaesthetic Revenue by segment (%) 21% of Group revenue 28% of Group gross profit Asia33 Americas25 Europe CIS 20 Africa Middle East13 Australasia9 Revenue Revenue 2024R’million 2023 R’million %ChangeReported CER Asia 3 112 4 701 (34) (35) Americas 2 395 1 955 23 12 Europe CIS 1 903 2 116 (10) (15) Africa Middle East 1 218 777 57 58 Australasia 856 836 2 – Total 9 484 10 385 (9) (12) Gross profit (%) 58,2 60,6 The Injectables portfolio returned to growth in FY2025, rising 4% (10% CER) to R9 885 million compared to the previous year. Africa Middle East revenue growth of 45% (48% CER) was boosted by the successful launch and roll-out of Mounjaro® in South Africa. The product swap transaction with Sandoz impacted Asia positively and Europe negatively. Solid growth in Americas (4% CER) and Australasia (13% CER) benefitting from improved product supply. The gross profit margin of 53,2% (compared to 58,2% in FY2024) was affected by the VBP in China and the related one-off inventory write-offs.